Clarithromycin: Clinical Overview
Clarithromycin is a macrolide antibiotic with established efficacy for pertussis, H. pylori eradication, non-tuberculous mycobacterial infections, and community-acquired respiratory infections, but carries significant drug interaction risks and specific contraindications that must be carefully evaluated before prescribing.
Primary Indications & Dosing
Pertussis (Treatment & Prophylaxis)
- Infants <1 month: NOT RECOMMENDED due to unknown risk of infantile hypertrophic pyloric stenosis (IHPS) 1
- Infants/children ≥1 month: 15 mg/kg/day (maximum 1 g/day) divided twice daily for 7 days 1
- Adults: 1 g/day in two divided doses for 7 days 1
H. pylori Eradication
Standard triple therapy (first-line when clarithromycin resistance <15%):
- Clarithromycin 500 mg twice daily + Amoxicillin 1000 mg twice daily + PPI (standard dose twice daily) for 14 days 2, 3
- This regimen achieves >90% eradication when local clarithromycin resistance is low 2
Sequential therapy (for high clarithromycin resistance areas):
- Days 1-5: PPI + Amoxicillin 1000 mg twice daily
- Days 6-10: PPI + Clarithromycin 500 mg twice daily + Metronidazole 500 mg twice daily 2
Non-Tuberculous Mycobacterial (NTM) Infections
Intermittent therapy (nodular/bronchiectatic disease):
- Clarithromycin 1000 mg three times weekly + Ethambutol 25 mg/kg + Rifampin 600 mg three times weekly 4
Daily therapy (fibrocavitary or severe disease):
- Clarithromycin 1000 mg/day (or 500 mg twice daily) + Ethambutol 15 mg/kg/day + Rifampin 10 mg/kg/day (max 600 mg) 4
- For patients with small body mass (<50 kg) or age >70 years, reduce to 500 mg/day or 250 mg twice daily due to GI intolerance 4
Pediatric NTM dosing:
- Ages 1 month-11 years: 7.5 mg/kg (max 500 mg) twice daily
- Ages 12-18 years: 500 mg twice daily 5
Community-Acquired Pneumonia
- Adults: 1 g every 24 hours for 7-14 days (extended-release formulation) 6
- Standard formulation: 500 mg twice daily 5
Absolute Contraindications
Do NOT prescribe clarithromycin with:
- History of hypersensitivity to any macrolide 1, 6
- Cisapride or pimozide (risk of fatal cardiac arrhythmias) 1, 6
- Astemizole or terfenadine (QT prolongation, torsades de pointes) 1
- History of cholestatic jaundice/hepatic dysfunction with prior clarithromycin use 6
- Colchicine in patients with renal or hepatic impairment 6
- Lomitapide, lovastatin, or simvastatin (risk of rhabdomyolysis) 6
- Ergot alkaloids (ergotamine, dihydroergotamine) 6
- Lurasidone 6
Critical Drug Interactions
Clarithromycin is a potent CYP3A4 inhibitor 1. Co-administration increases concentrations of CYP3A4-metabolized drugs, potentially causing serious toxicity:
High-risk interactions requiring dose adjustment or avoidance:
- Statins: Use atorvastatin or pravastatin instead; avoid lovastatin/simvastatin 6
- Calcium channel blockers: Monitor for hypotension, bradycardia
- Benzodiazepines (triazolam, alprazolam, midazolam): Enhanced sedation
- Immunosuppressants (cyclosporine, tacrolimus): Monitor drug levels closely
- Anticoagulants (warfarin): Monitor INR frequently 1
- Antiarrhythmics (Class IA/III): Increased QT prolongation risk 6
- Theophylline: Monitor levels, risk of seizures 1
- Digoxin: Monitor levels 1
- Carbamazepine, phenytoin: Increased levels 1
Warnings & Precautions
QT Prolongation
Avoid clarithromycin in patients with:
- Known QT prolongation or congenital long QT syndrome
- Uncorrected hypokalemia or hypomagnesemia
- Significant bradycardia
- Concurrent use of other QT-prolonging drugs
- Ventricular arrhythmias including torsades de pointes 6
Cardiovascular Risk
- Increased risk of all-cause mortality ≥1 year post-treatment in patients with coronary artery disease 6
- Balance this risk against treatment benefits in CAD patients
Hepatotoxicity
- Discontinue immediately if signs/symptoms of hepatitis develop 6
- Monitor liver function in patients with hepatic impairment 1
Renal Impairment
- Severe renal impairment (CrCl <30 mL/min): Reduce dose by 50% or double dosing interval 1
- Moderate impairment with atazanavir/ritonavir: Reduce dose 6
- No adjustment needed for hepatic impairment alone 1
Myasthenia Gravis
- Exacerbation reported; use with extreme caution 6
Pregnancy & Lactation
- FDA Pregnancy Category C 1
- Animal studies show adverse fetal effects
- Not recommended in pregnancy except when no alternative exists 6
Common Adverse Effects
Gastrointestinal (most frequent):
- Epigastric distress, abdominal pain (2%)
- Diarrhea (3-6%)
- Nausea (3%)
- Vomiting (6%)
- Dysgeusia/taste perversion (3-19%) 1, 5, 1
Serious but rare:
- Anaphylaxis
- Stevens-Johnson syndrome, toxic epidermal necrolysis
- Hepatotoxicity, hepatic failure
- QTc prolongation, cardiac arrest, torsades de pointes
- Ototoxicity (hearing loss, tinnitus with long-term use)
- Clostridioides difficile-associated diarrhea 5, 6
Monitoring Requirements
For NTM treatment:
- Baseline: ECG, audiometry, CBC, renal/hepatic function 5
- During therapy: ECG at 2 weeks and after adding QT-prolonging drugs; repeat audiometry if symptomatic 5
- Routine: Intermittent CBC, renal/hepatic function throughout treatment 5
Alternative Therapies
For Pertussis
- Azithromycin (preferred for infants <1 month; better tolerated than clarithromycin) 1
- TMP-SMZ (for patients ≥2 months with macrolide contraindication or resistance) 1
For H. pylori
- Levofloxacin-based triple therapy (second-line if clarithromycin fails): Levofloxacin 500 mg daily + Amoxicillin 1000 mg twice daily + PPI for 10 days 2, 3
- Bismuth quadruple therapy (clarithromycin-free option) 3, 7
- Rifabutin triple therapy (for multiple treatment failures) 3, 7
For Respiratory Infections
- Azithromycin: Fewer drug interactions (does not inhibit CYP3A4), once-daily dosing 1
- Beta-lactams or cephalosporins for appropriate pathogens
Key Clinical Pearls
Never use in infants <1 month due to IHPS risk 1
Check medication list thoroughly before prescribing—CYP3A4 interactions are extensive and potentially fatal 1
For H. pylori: Only use empirically if local clarithromycin resistance <15%; otherwise, obtain susceptibility testing or use alternative regimen 2, 3
For NTM: Gradual medication introduction (one drug every 1-2 weeks) improves tolerance in elderly patients 4
Oral bioavailability is 52-55%—oral and IV formulations are therapeutically equivalent for most indications when GI absorption is intact 8, 9
Better tolerated than erythromycin with similar efficacy but significantly fewer GI side effects 1, 10, 11
Tissue penetration is excellent—achieves high concentrations in respiratory tract, saliva, sputum, and alveolar macrophages 8, 10, 11